Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.H Lundbeck A/S, a company focused on treating CNS disorders, has entered into a collaboration agreement with Proximagen Group.
Subscribe to our email newsletter
Under the agreement, Lundbeck and Proximagen will jointly apply their expertise in CNS drug development.
As part of the agreement, a steering committee involving experts from both companies will focus on developing three of Proximagen’s programmes, with the aim of identifying innovative therapies to treat serious diseases including epilepsy, pain and inflammatory disorders.
Lundbeck Research and Development executive vice president Anders Gersel Pedersen said this strategic partnership will provide Lundbeck with exposure to some very exciting research programmes.